Medical Device Spinal Muscular Atrophy Market | Page 3

REPORT DESCRIPTION
Spinal Muscular Atrophy Market Dynamics:
Major factors driving growth of the spinal muscular atrophy market includes increasing number of clinical
trials and rising government support for R&D. Biotechnology and biopharmaceutical companies are
working towards development of effective therapies to treat spinal muscular atrophy. For instance, in 2016,
the U.S. FDA approved Spinraza (nusinersen) drug from Biogen for the treatment of SMA. Spinraza targets
the underlying defect in SMA, so it can help prevent, delay, or even reverse the symptoms.
However, its common side effects include higher risk of constipation and respiratory tract infection along
with minimal risk of kidney problems and bleeding. Moreover, the cost of research for development of new
therapy is also high. With the advancements of drug in the pipeline, its expense and time for development
also increases. According to Cure SMA, it can take over 15 years and US$ 100 million for a single drug
candidate to reach FDA approval. These factors make research challenging particularly for a disease such
as SMA. These factors are expected to hinder growth of the market.
Download PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/1920